<SEC-DOCUMENT>0001193125-21-153334.txt : 20210506
<SEC-HEADER>0001193125-21-153334.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506162552
ACCESSION NUMBER:		0001193125-21-153334
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Relay Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001812364
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-255583
		FILM NUMBER:		21898221

	BUSINESS ADDRESS:	
		STREET 1:		399 BINNEY STREET
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-370-8837

	MAIL ADDRESS:	
		STREET 1:		399 BINNEY STREET
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d132252d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(4)<BR>Registration No. 333-255583<BR> </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g132252g96c16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>1,883,487 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered
by the Selling Stockholders </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the proposed resale or other disposition by the selling stockholders identified in this prospectus, or the selling stockholders, of
1,883,487 shares of our common stock, or the Shares. The Shares being offered were issued and sold in a private placement in connection with our acquisition of ZebiAI Therapeutics, Inc., which closed on April&nbsp;22, 2021. We are not selling any
Shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of Shares by the selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
selling stockholders may sell the Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of
these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading &#147;Plan of Distribution&#148; elsewhere in
this prospectus for more information about how the selling stockholders may sell or otherwise dispose of their Shares hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders
may sell any, all or none of the Shares offered by this prospectus and we do not know when or in what amount the selling stockholders may sell their Shares hereunder following the effective date of the registration statement of which this prospectus
forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should carefully read this prospectus, as well as any documents incorporated by reference, before you invest in any of the securities
being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market under the symbol &#147;RLAY.&#148; The last reported sale price of our common stock
on the Nasdaq Global Market on April&nbsp;23, 2021 was $33.34. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as that term is used in the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act, and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock involves risks. See &#147;<A HREF="#rom132252_3">Risk Factors</A>&#148; on page 10. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is May 6, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_6">DIVIDEND POLICY .</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_7">SELLING STOCKHOLDERS.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_8">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_9">CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom132252_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference important information into this prospectus. You may obtain the information incorporated by
reference without charge by following the instructions under &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information
contained in or incorporated by reference in this prospectus or in any free writing prospectus we file with the Securities and Exchange Commission, or the SEC. Neither we nor the selling stockholders have authorized anyone to provide you with
information other than that contained in or incorporated by reference in this prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as
to the reliability of, any other information that others may give you. The selling stockholders are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The information contained in
this prospectus is accurate only as of the date on the front cover page of this prospectus, or other earlier date stated in this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your
investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes incorporated by reference in this prospectus. You should also
consider, among other things, the matters described under &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, in each case incorporated by reference in this prospectus. Unless the context otherwise requires, the terms &#147;Relay,&#148; &#147;Relay Therapeutics,&#148;
&#147;the Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; in this prospectus refer to Relay Therapeutics, Inc. and its subsidiary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage precision medicines
company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. We are among the first of a new breed of biotech created at the intersection of disparate disciplines. Our Dynamo<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> platform integrates an array of leading-edge computational and experimental approaches to effectively drug protein targets that have previously been intractable. Our initial focus is on
enhancing small molecule therapeutic discovery in targeted oncology and genetic disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a pipeline of medicines to address targets in
precision oncology, including our lead product candidates, <FONT STYLE="white-space:nowrap">RLY-1971</FONT> and <FONT STYLE="white-space:nowrap">RLY-4008,</FONT> as well as our PI3K&#945; mutant selective program, or the <FONT
STYLE="white-space:nowrap">RLY-PI3K1047</FONT> program. We initiated a Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">RLY-1971,</FONT> our inhibitor of Src homology region 2 domain-containing
<FONT STYLE="white-space:nowrap">phosphatase-2,</FONT> or SHP2, in patients with advanced solid tumors in the first quarter of 2020. In December 2020, we entered into a global collaboration and license agreement, or the Genentech Agreement, with
Genentech, Inc., a member of the Roche Group, or Genentech, for the development and commercialization of <FONT STYLE="white-space:nowrap">RLY-1971.</FONT> We initiated a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial of <FONT STYLE="white-space:nowrap">RLY-4008,</FONT> our inhibitor of fibroblast growth factor receptor 2, or FGFR2, enriched for patients
with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. We anticipate the <FONT STYLE="white-space:nowrap">RLY-PI3K1047</FONT> program, our program for molecules targeting cancer-associated mutant variants of
phosphoinostide <FONT STYLE="white-space:nowrap">3-kinase</FONT> alpha, or PI3K&#945;, to be in Investigational New Drug, or IND, enabling studies in 2021. While our initial focus is on precision oncology, we believe our Dynamo platform may also be
broadly applied to other areas of precision medicine, such as genetic disease. In addition to the three product candidates described above, we have five discovery stage programs across precision oncology and genetic disease. We are focused on using
the novel insights derived from our approach to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of our therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision medicine emerged as an approach for disease treatment as the understanding of the link between genetic alterations, protein dysfunction and diseases
evolved. Precision medicine aims to specifically and potently drug genetically validated target proteins (i.e., genetic variants potentially implicated in biology of disease). However, some target proteins thus far have been intractable using
conventional drug discovery tools, such as structure-based drug design, or SBDD. While SBDD is well-suited to solving some drug discovery problems such as orthosteric site kinase inhibitors, its reliance on static images of protein fragments limits
its ability to gain accurate insights into the dynamic behavior of proteins in their natural state, which in turn limits its ability to discover medicines with exquisite specificity. Our approach pivots the understanding of protein targets from the
industry-standard, static view, to a novel paradigm based on fundamental insights into protein motion. We then apply these novel insights into protein motion to drug discovery and design, which we term Motion Based Drug Design<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP>, or MBDD. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The confluence of three forces &#151; the proliferation of readily available genomic data, the evolution of
experimental techniques, and advancements in computational power and speed &#151; led to the founding of Relay Therapeutics. We believe we are uniquely situated in our ability to consolidate these advances and, when combined with our world-class
team of both experimental and computational experts, integrate these solutions into MBDD to create medicines that will make a transformative difference for patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Key Drug Discovery Steps of Our Dynamo Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Dynamo platform puts protein motion at the center of drug discovery and design, integrating a broad and tailored array of leading-edge experimental and
computational approaches, including deploying the Anton&nbsp;2 supercomputer, which was custom-built by D. E. Shaw Research, LLC, or D. E. Shaw Research, to perform molecular dynamic simulations of proteins. We have access to the Anton&nbsp;2
supercomputer, which we believe to be the only resource of computational power of its caliber, through our collaboration with D. E. Shaw Research, LLC, or D.E. Shaw Research, pursuant to which we collaborate with D.&nbsp;E.&nbsp;Shaw Research to
rapidly develop various protein models. Our use of the Anton&nbsp;2 supercomputer and our collaboration with D.E.&nbsp;Shaw Research is subject to the terms and conditions of the Amended and Restated Collaboration and License Agreement with D. E.
Shaw Research, or the DESRES Agreement. We deploy the power of the platform in three key phases of MBDD discovery: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Target Modulation Hypothesis. </B>By generating fundamental insights into the structure and conformational
dynamics of full-length proteins, our Dynamo platform enables us to model a target protein&#146;s function, to develop unique motion-based hypotheses for how to modulate the protein&#146;s behavior, and to identify potential novel binding sites for
new therapeutic agents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Hit Finding and Lead Generation. </B>The integration of our computational and experimental platforms affords a
deeper functional understanding of our targets and enables the design of physiologically relevant activity-based, ligand-centric and computational screens. These highly differentiated screens have the ability to yield a larger number of chemical
series and potential therapies to proceed into lead optimization than conventional experimental techniques alone. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Lead Optimization. </B>Our Dynamo platform uses advanced computational models in tight integration with our
medicinal chemistry, structural biology, enzymology and biophysics capabilities to predict, design and experimentally evaluate compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and
drug-like properties. We believe our approach enables us to converge on optimized compounds with much greater efficiency than conventional approaches, which are typically highly iterative over an extended timeframe. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Dynamo platform has the potential to address a diverse range of disease targets, including those proteins that have not been addressed selectively and
potently with existing therapies. While we have initially focused our Dynamo platform on small molecule drug discovery in the area of precision oncology, we believe it could be readily deployed across broader precision and genetic medicine areas as
well as other therapeutic modalities, such as protein therapeutics and antibody design. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have deployed our technology platform to build a pipeline of product candidates to address targets in precision oncology, where there is clear evidence
linking target proteins to disease and where molecular diagnostics can unambiguously identify relevant patients for treatment. We believe this approach will increase the likelihood of successfully translating a specific pharmacological mechanism
into clinical benefit. The targets associated with all of our current programs are Category 1 Targets under our DESRES Agreement. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g132252g10p63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">RLY-4008</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">RLY-4008</FONT> is designed to be an oral, small molecule, selective inhibitor of fibroblast growth factor receptor 2, or
FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties.
<FONT STYLE="white-space:nowrap">RLY-4008</FONT> demonstrates FGFR2-dependent killing in cancer cell lines, while showing minimal inhibition of other targets, including other members of the FGFR family. We initiated a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial of <FONT STYLE="white-space:nowrap">RLY-4008</FONT> enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in
September 2020. We anticipate giving an initial clinical update on this trial in the second half of 2021. We believe FGFR2-mediated cancers affect approximately 8,000 late-line patients annually in the United States. In the future, if <FONT
STYLE="white-space:nowrap">RLY-4008</FONT> advances to earlier lines of treatment, we believe it could potentially address approximately 20,000 patients annually in the United States.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mutant-PI3K</I>&#945;<I> Inhibitor Program </I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">RLY-PI3K1047</FONT> is a lead compound in our franchise of programs targeting cancer-associated mutant variants of phosphoinositide <FONT STYLE="white-space:nowrap">3-kinase</FONT> alpha, or PI3K&#945;. <FONT
STYLE="white-space:nowrap">RLY-PI3K1047</FONT> is a small molecule inhibitor of PI3K&#945; that we designed specifically to target PI3K&#945; H1047X mutants via a previously undescribed allosteric mechanism. Oral dosing of <FONT
STYLE="white-space:nowrap">RLY-PI3K1047</FONT> resulted in tumor growth inhibition in mouse xenograft models of PI3K&#945; H1047R mutant carcinoma. We expect to begin <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for a differentiated
PI3K&#945; H1047X mutant-selective inhibitor in 2021. We believe PI3K&#945; H1047X mutant cancers affect approximately 10,000 late-line patients annually in the United States. In the future, if <FONT STYLE="white-space:nowrap">RLY-PI3K1047</FONT>
advances to earlier lines of treatment, we believe it could potentially be suitable for use in approximately 50,000 patients annually in the United States.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two additional mutations of interest for our PI3K&#945; franchise are E542X and E545X. We estimate there are approximately 15,000 late-line and 60,000 total
patients annually in the United States who might benefit from a PI3K&#945; targeted inhibitor that targets the mutations at E542 and E545. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">RLY-1971</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">RLY-1971</FONT> binds and stabilizes SHP2 in its inactive conformation.
SHP2 promotes cancer cell survival and growth through the RAS pathway by transducing signals downstream from receptor tyrosine kinases, or RTKs. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additionally, activating SHP2 mutations causes enhanced signaling in the absence of ligand stimulation and has been identified as an oncogenic driver in a range of tumors. As a critical signaling
node and regulator, SHP2 drives cancer cell proliferation and plays a key role in the way cancer cells develop resistance to targeted therapies. We believe that inhibition of SHP2 could be effective as a monotherapy in cancers with specific
alterations and could block a common path that cancer cells exploit to resist other antitumor agents, thus overcoming or delaying the onset of resistance to those therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently evaluating the safety and tolerability of <FONT STYLE="white-space:nowrap">RLY-1971</FONT> in a Phase 1 dose escalation study in patients
with advanced or metastatic solid tumors. In December 2020, we entered into the Genentech Agreement, a global collaboration and license agreement with Genentech for the development and commercialization of
<FONT STYLE="white-space:nowrap">RLY-1971.</FONT> Future development for <FONT STYLE="white-space:nowrap">RLY-1971</FONT> will be governed by a joint development team between us and Genentech. We expect a combination trial of <FONT
STYLE="white-space:nowrap">RLY-1971</FONT> and Genentech&#146;s KRAS<SUP STYLE="font-size:85%; vertical-align:top">G12C </SUP>inhibitor, <FONT STYLE="white-space:nowrap">GDC-6036,</FONT> to be initiated in 2021. Given the range of cancers that are
related to SHP2 dependence, we believe <FONT STYLE="white-space:nowrap">RLY-1971</FONT> could serve as a backbone for compelling combination therapies. We believe SHP2-mediated cancers affect approximately 55,000 late-line patients annually in
combination therapy settings in the United States. In the future, if <FONT STYLE="white-space:nowrap">RLY-1971</FONT> advances to earlier lines of treatment, we believe it could potentially have applicability to approximately 90,000 patients
annually in the United States.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Genentech Agreement, we have received
$75&nbsp;million in an upfront payment and are eligible to receive $25&nbsp;million in near-term payments; and, if we do not opt into a U.S. profit/cost share, up to $695&nbsp;million in additional development, commercialization and sales-based
milestones for <FONT STYLE="white-space:nowrap">RLY-1971;</FONT> and tiered royalties on annual global net sales (on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis), in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid-teens,</FONT></FONT></FONT> subject to reduction in certain circumstances. Additionally, we are eligible to receive additional royalties in the
event of regulatory approval of <FONT STYLE="white-space:nowrap">RLY-1971</FONT> and Genentech&#146;s compound, <FONT STYLE="white-space:nowrap">GDC-6036,</FONT> that directly binds to and inhibits
KRAS<SUP STYLE="font-size:85%; vertical-align:top">G12C</SUP>, in combination. We have the right to <FONT STYLE="white-space:nowrap">opt-in</FONT> to a 50/50 U.S. profit/cost share and if we do opt into the U.S. profit/cost share, we are eligible to
receive up to $410&nbsp;million in additional commercialization and sales-based milestones for <FONT STYLE="white-space:nowrap">RLY-1971</FONT> outside of the U.S. and tiered royalties on annual net sales outside of the U.S. (on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis), in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid-teens,</FONT></FONT></FONT>
subject to reduction in certain circumstances. We also retain the right to develop <FONT STYLE="white-space:nowrap">RLY-1971</FONT> in combination with our FGFR2 and PI3K&#945; programs. If we elect to <FONT STYLE="white-space:nowrap">opt-out</FONT>
of the profit/cost share, then the milestone and royalty payment obligations will revert to the financial terms that would be applicable if we had not opted into the profit/cost share, with certain adjustments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Discovery Programs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are deploying our Dynamo platform
and MBDD approach to advance multiple discovery-stage precision oncology programs. As with our lead programs, these programs leverage insights into protein conformational dynamics to address high-value, genetically validated oncogenes that
previously have been intractable to conventional drug-discovery approaches. Our Dynamo platform&#146;s protein visualization capabilities can be applied to multiple therapeutic areas beyond precision oncology. To further diversify our pipeline, we
are leveraging our Dynamo platform to address validated targets in monogenic diseases, where genetic alterations lead to disease-causing defects in protein motion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Strategy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our mission is to leverage unique
insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies. We believe that, by placing protein
motion at the heart of MBDD discovery, our unique Dynamo platform has the potential to address previously intractable precision medicine targets. To accomplish this, we intend to continue building a team that shares our commitment to patients, to
continue to enhance our </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
platform, and to rapidly advance our precision medicine pipeline of product candidates. The key elements of our strategy are to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rapidly advance our lead precision oncology programs, <FONT STYLE="white-space:nowrap">RLY-4008</FONT> and
<FONT STYLE="white-space:nowrap">RLY-PI3K1047,</FONT> through clinical development and regulatory approval. We believe our lead precision oncology programs have the potential to treat a wide variety of cancers either as monotherapy or in combination
regimens. In September 2020, we initiated a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial of <FONT STYLE="white-space:nowrap">RLY-4008.</FONT> In 2021, we expect to have early safety
and efficacy data for <FONT STYLE="white-space:nowrap">RLY-4008</FONT> and to be in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for our <FONT STYLE="white-space:nowrap">RLY-PI3K1047</FONT> program. For our wholly-owned programs, we
plan to conduct our clinical studies in genetically-defined patient populations. To potentially mitigate development risks, we will leverage learnings from recently approved precision oncology drugs to inform the clinical and regulatory pathways for
our lead oncology programs. If we are successful in achieving clinically meaningful anti-tumor activity across solid tumor types, we plan to meet with regulatory authorities to discuss expedited regulatory approval strategies. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Continue to enhance our unique drug-discovery platform.</B> Our Dynamo platform uniquely integrates a broad range of leading-edge experimental and
computational technologies and tools, providing us with fundamental insights into the conformational dynamics of target proteins. We are committed to continuously integrating new computational and experimental tools, technologies and capabilities to
enhance the power of our Dynamo platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Harness the insights and data generated from our platform against intractable targets in oncology and other
therapeutic areas. </B>We have built a drug discovery process that leverages our collaboration with D. E.&nbsp;Shaw Research and their access to the Anton 2 supercomputer and our proprietary computational workflows. We are committed to deploying our
Dynamo platform against targets in additional therapeutic areas beyond oncology. Our next focus, outside of oncology, is on rare genetic diseases where protein targets are genetically validated, where defects in protein conformational dynamics are
abundant, and where we believe our approach is well-suited to identify therapies with the potential to have transformative impact for patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selectively enter into strategic collaborations to maximize the value of our platform and pipeline.</B> We have initiated a Phase 1 clinical trial for <FONT
STYLE="white-space:nowrap">RLY-1971</FONT> in patients with advanced solid tumors in the first quarter of 2020 and have continued to advance the clinical development of <FONT STYLE="white-space:nowrap">RLY-1971.</FONT><B> </B>In December 2020, we
entered into the Genentech Agreement, a global collaboration and license agreement with Genentech for the development and commercialization of <FONT STYLE="white-space:nowrap">RLY-1971.</FONT> Other than our SHP2 program, we retain full development
and commercialization rights to our current pipeline of precision medicine programs. We intend to build a fully integrated biopharmaceutical company and independently pursue the development and commercialization of our key product candidates. Given
our potential to generate novel product candidates addressing a wide variety of therapeutic indications, we may enter into additional strategic partnerships around certain targets, product candidates, disease areas or geographies. If we believe
these collaborations could accelerate the development and commercialization of our product candidates, and allow us to realize additional potential in our product candidates and our platform. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquisition of ZebiAI
Therapeutics </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2021, we entered into an Agreement and Plan of Merger, or the Merger Agreement, to acquire ZebiAI Therapeutics, Inc.,
or ZebiAI. Pursuant to the terms of the Merger Agreement, at the closing of the acquisition on April&nbsp;22, 2021, we paid the former stockholders, optionholders and warrant holders of ZebiAI, or the ZebiAI Holders, upfront consideration consisting
of approximately $20.0&nbsp;million in cash and 1,883,487 shares of our common stock, excluding customary purchase price adjustments. Under the terms of the Merger </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, we agreed to register for resale the shares of our common stock that we issued as payment for the equity portion of the upfront consideration. The 1,883,487 shares of our common stock
we issued as payment for the equity portion of the upfront consideration are the shares being registered for resale hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, (i) the ZebiAI
Holders will be eligible to receive up to an additional $85.0&nbsp;million in milestone payments upon the achievement of certain platform or program-related milestones, payable in our common stock valued using the volume-weighted average price over
the five trading day period ending on the last trading day prior to the date on which the applicable milestone is achieved and (ii) we will pay the ZebiAI Holders 10% of the payments received by us within three years of the closing date of the
Merger Agreement from partnering, collaboration or other agreements related to ZebiAI&#146;s platform, up to an aggregate maximum amount of $100.0&nbsp;million, payable in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the closing of the Merger Agreement, we continue to expect that our current cash, cash equivalents and investments will enable us to fund our operating
expenses and capital expenditure requirements into 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are
described more fully in the section entitled &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020 incorporated by reference in this prospectus. These risks
include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have never successfully completed any clinical trials, and we may be unable to do so for any product
candidates we develop. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of
necessary regulatory approvals could be delayed or prevented. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Positive results from early preclinical studies of our product candidates are not necessarily predictive of the
results of later preclinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive results from our earlier preclinical studies of our product candidates in our later preclinical studies and future
clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our current or future clinical trials may reveal significant adverse events not seen in our preclinical or
nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are
currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The incidence and prevalence for target patient populations of our product candidates have not been established
with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will
be adversely affected, possibly materially. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products
before or more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product
candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under the DESRES Agreement, we collaborate with D. E. Shaw Research to rapidly develop various protein models, a
process that depends on D. E. Shaw Research&#146;s use of their proprietary supercomputer, Anton 2. A termination of the DESRES Agreement could have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our ongoing clinical trials of
<FONT STYLE="white-space:nowrap">RLY-1971</FONT> and <FONT STYLE="white-space:nowrap">RLY-4008</FONT> and expect to rely on third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of our product candidates.
If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our
business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may enter into collaborations with third parties for the research, development, manufacture and
commercialization of one or more of our programs or product candidates. If these collaborations are not successful, our business could be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a biopharmaceutical company with a limited operating history. We have incurred significant operating
losses since our inception and anticipate that we will incur continued losses for the foreseeable future. We have no products approved for commercial sale and have not generated any revenue from product sales. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be
forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A pandemic, epidemic, or outbreak of an infectious disease, such
<FONT STYLE="white-space:nowrap">as&nbsp;COVID-19,</FONT> may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to adequately protect our proprietary technology or obtain and maintain patent protection for
our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully
commercialize our technology and products may be impaired. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing
regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions,
and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an &#147;emerging growth company&#148; as defined in the JOBS Act and a &#147;smaller reporting
company&#148; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and may avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make
our common stock less attractive to investors and adversely affect the market price of our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate history </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware on May&nbsp;4, 2015 under the name &#147;Allostery, Inc.&#148; Our principal corporate office is
located at 399 Binney Street, 2nd Floor, Cambridge, MA 02139, and our telephone number is (617) <FONT STYLE="white-space:nowrap">370-8837.</FONT> Our website address is www.relaytx.com. We do not incorporate the information on or accessible through
our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own various U.S. federal trademark applications and unregistered trademarks, including our company name.
All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent
under applicable law, their rights thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended. As an emerging growth company,
we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to only two years of audited financial statements in addition to any required unaudited interim
financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any
golden parachute arrangements not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth
company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal
year following the fifth anniversary of the date of our initial public offering in July 2020, or IPO; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the
last day of the fiscal year in which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$700&nbsp;million as of the prior June 30th. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be
different from the information you receive from other public companies in which you hold stock. We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain
conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation, providing an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to
Section&nbsp;404(b) of the Sarbanes-Oxley Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be
a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting
and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $250&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenues
are more than $100&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than
$700&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock to be offered by the selling stockholders hereunder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1,883,487 shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We will not receive any proceeds from the sale of our shares of common stock by the selling stockholders. See &#147;Use of Proceeds.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plan of Distribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The selling stockholders may sell all or a portion of the shares of common stock beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. Registration of
the common stock covered by this prospectus does not mean, however, that such shares necessarily will be offered or sold. See &#147;Plan of Distribution.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">This investment involves a high degree of risk. You should read the description of risks set forth under &#147;<A HREF="#rom132252_3">Risk Factors</A>&#148; beginning on page 10 of this prospectus and the documents incorporated by
reference herein for a discussion of factors to consider before deciding to purchase our securities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nasdaq Global Market Symbol</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;RLAY&#148;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks and other
information described in, or incorporated by reference into, this prospectus, including the risks and uncertainties discussed in the &#147;Risk Factors&#148; sections in this prospectus, our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2020 and any subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated by reference herein in their entirety.
Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. If any of the risks incorporated by reference herein occur, our business, financial condition and operating results
could be harmed, the trading price of our common stock could decline and you could lose part or all of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains express or implied forward-looking statements that are based on our
management&#146;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or
our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or
achievements expressed or implied by these forward-looking statements. Forward-looking statements in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and
future preclinical and clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our
research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and
develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture our drug substances, delivery vehicles, and product
candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability and willingness of our third-party strategic collaborators to continue research and development
activities relating to our development candidates and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and commercialization
of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, and strategic plans for our business, product candidates, and
technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations
or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future agreements with third parties in connection with the commercialization of product candidates and any other
approved product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing
cost; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> including mitigation
efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors&#148; in our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify
forward-looking statements by terminology such as &#147;may,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148;
&#147;potential,&#148; &#147;continue,&#148; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things,
those listed under the section titled &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020 and elsewhere in or incorporated by reference in this prospectus. If
one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking
statement is a guarantee of future performance. You should read this prospectus and the documents that we incorporate by reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration
statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not
rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus also
contains or incorporates by reference estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or
similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry,
business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications,
government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in or incorporated by reference in this prospectus, their estimates, in particular as they relate to projections,
involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders will make offers and sales pursuant to this prospectus. We will not receive any of the proceeds of such offerings. The selling
stockholders will pay any underwriting discounts and commissions and expenses they incur for brokerage, accounting, tax or legal services, or any other expenses they incur in disposing of their shares. We will incur certain expenses in connection
with the registration with the SEC of the shares of our common stock to be sold by the selling stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the
growth and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on
our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash
dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale of shares of our common stock held by the selling stockholders listed in the table below. The selling stockholders
acquired these shares from us in a private offering pursuant to an exemption from registration afforded by Section&nbsp;4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder as partial consideration for our acquisition of ZebiAI
Therapeutics, Inc. on April&nbsp;22, 2021. Under the Merger Agreement and related Registration Rights Agreement, we agreed to file a registration statement or prospectus with the SEC for the purposes of registering for resale the shares of our
common stock issued to the selling stockholders and to maintain the effectiveness of the registration statement until such time as all shares of common stock covered by the registration statement have been sold or may be sold under Rule 144 without
manner of sale restrictions or volume limitations, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the names of the selling stockholders,
the number of shares of common stock owned beneficially by the selling stockholders as of April&nbsp;22, 2021, and the number of shares of our common stock that may be offered by the selling stockholders pursuant to this prospectus. The table and
the other information contained under the captions &#147;Selling Stockholders&#148; and &#147;Plan of Distribution&#148; has been prepared based upon information furnished to us by or on behalf of the selling stockholders. The following table sets
forth, as to each of the selling stockholders, the number of shares beneficially owned, the number of shares being sold, the number of shares beneficially owned upon completion of the offering and the percentage beneficial ownership upon completion
of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules&nbsp;of the SEC and includes voting or investment power with respect to
the securities. The percentage of shares beneficially owned prior to and after the offering is based on 90,650,933 shares of our common stock outstanding as of April&nbsp;22, 2021.&nbsp;Except as otherwise indicated, each of the selling stockholders
has sole voting and investment power with respect to all shares of capital stock held by it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon information provided by the selling stockholders,
unless otherwise set forth in the footnotes to the table below, none of the selling stockholders nor any of their affiliates, officers, directors or principal equity holders has had any positions or office or has had any material relationship with
us within the past three years. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name&nbsp;and&nbsp;Address&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Selling&nbsp;Stockholder(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Before&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Offered<BR>by This<BR>Prospectus</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>After&nbsp;Offering(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Patrick Walters(2) </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">342,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Richard Wagner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">501,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">501,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Google LLC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1600 Amphitheatre Parkway</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mountain View, CA 94043</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">231,971</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">231,971</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">X-Chem,</FONT> Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Beaver St., Suite 100</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">204,135</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">204,135</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Brant C. Binder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>BCB Irrevocable 2015 Trust</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>BINDER TRUST, dated 15&nbsp;July 2003</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Anterra F&amp;A Ventures II Co&ouml;peratief U.A.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Herengracht 454, 1017 CA</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amsterdam, The Netherlands</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">417,547</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">417,547</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All other selling stockholders as a group holding less than 1% of outstanding shares in the
aggregate (39 individuals)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,225,516</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2.46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,883,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>342,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>*</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent (1%). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise noted, the address of the selling stockholder is c/o Relay Therapeutics, Inc. 399 Binney St.,
2nd Floor, Cambridge, MA 02139. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patrick Walters is our Senior Vice President, Computation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not know when or in what amounts a selling stockholder may offer shares for sale. The selling
stockholders might not sell any or all of the shares offered by this prospectus. Because the selling stockholders may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements or
understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the selling stockholders after completion of the offering. However, for purposes of this table, we have assumed that,
after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
Merger Agreement and Registration Rights Agreement, we will indemnify each selling stockholder against any damages to which a selling stockholder may become subject by reason of any material misstatement or omission in this registration statement,
except to the extent that such damages arise out of or are based upon information furnished to us in writing by such selling stockholder for use in this registration statement. Each selling stockholder will indemnify us and certain related persons
against any damages to which such indemnified parties may become subject by reason of any material misstatement or omission in this registration statement or any violation or alleged violation of the Securities Act, the Exchange Act, or any state
securities law, or any rule promulgated under any of the foregoing, in each case to the extent based upon any action or omission made in reliance upon information provided in writing by such selling stockholder for use in this registration
statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_8"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following descriptions are summaries of the material terms of our fourth amended and restated certificate of incorporation and amended and restated
bylaws. We refer in this section to our fourth amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our amended and restated bylaws as our bylaws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of One
Hundred Fifty Million (150,000,000) shares of common stock, par value $0.001 per share and Ten Million (10,000,000) shares of undesignated preferred stock, par value $0.001 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of our common stock are
entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends
declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription
rights or redemption or sinking fund provisions. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and
any liquidation preference of any outstanding preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market under the trading symbol
&#147;RLAY.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the
authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could
include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights
of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance
of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. No shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain holders of our
common stock are entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of a second amended and restated investors&#146; rights agreement between us and the holders
of our preferred stock. The second amended and restated investors&#146; rights agreement includes demand registration rights, short-form registration rights, and piggyback registration rights. All fees, costs and expenses of underwritten
registrations under this agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand registration rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain holders of our common stock, are entitled to demand registration rights. Under the terms of the second amended and restated investors&#146; rights
agreement, we will be required, upon the written request of a majority of holders of the registrable securities then outstanding that would result in an aggregate offering price of at least $7.5&nbsp;million, to file a registration statement and to
use commercially reasonable efforts to effect the registration of all or a portion of these shares for public resale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Short-Form registration
rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our second amended and restated investors&#146; rights agreement, if we are eligible to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> upon the written request of at least 10% in interest of these holders to sell registrable securities at an aggregate price of at least $1.0&nbsp;million, we will be required to use commercially reasonable
efforts to effect a registration of such shares. We are required to effect only two registrations in any twelve-month period pursuant to this provision of the second amended and restated investors&#146; rights agreement. The right to have such
shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback
registration rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our second amended and restated investors&#146; rights agreement, if we register any of our securities either for
our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain exceptions contained in the second amended and restated investors&#146; rights
agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our second amended and restated
investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement
attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of registration
rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The demand registration rights and short form registration rights granted under our second amended and restated investors&#146; rights
agreement will terminate on the fifth anniversary of the completion of our initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover effects of our certificate of
incorporation and bylaws and Delaware law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of
delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT
STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board composition and
filling vacancies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered
three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of
<FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the
size of our board, may only </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors
and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No
written consent of stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the
stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of
our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of
stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to
those matters properly brought before the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance notice requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new
business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally,
to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form
and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to certificate of incorporation and bylaws </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of
incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the
provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less
than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any
limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating
to notice of stockholder business and nominations and special meetings must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred
stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause
shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this
regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of
earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing
a change in control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
bylaws provide that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware
or other state courts of the State of Delaware) will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by
any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of
incorporation or bylaws; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Our bylaws also
provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule
that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the United States District Court in the District
of Massachusetts will be the exclusive forum for any private action asserting violations by us or any of our directors or officers of the Securities Act or the Exchange Act, or the rules and regulations promulgated thereunder, and of all suits in
equity and actions at law brought to enforce any liability or duty created by those statutes or the rules and regulations under such statutes. If any action the subject matter of which is within the scope of the preceding sentence is filed in a
court other than the United States District of Massachusetts, the plaintiff or plaintiffs shall be deemed by this provision of the bylaws (i)&nbsp;to have consented to removal of the action by us to the United States District Court in the District
of Massachusetts, in the case of an action filed in a state court, and (ii)&nbsp;to have consented to transfer of the action to the United States District Court in the District of Massachusetts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203 of the Delaware general corporation law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly held Delaware
corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is
approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested
stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the
assets of the corporation; subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested stockholder as any entity
or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed
on the Nasdaq Global Market under the trading symbol &#147;RLAY.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer agent and registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is 250 Royall
Street, Canton, Massachusetts 02021, and its telephone number is (800) <FONT STYLE="white-space:nowrap">962-4284.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_9"></A>CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of certain material U.S. federal income tax
considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion,
a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax
purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships or other entities or arrangements that are treated as pass-through
entities for U.S. federal income tax purposes or persons that hold their shares of our common stock through partnerships or such other pass-through entities. The tax treatment of a partner in a partnership or other entity or arrangement that is
treated as a pass-through entity for U.S. federal income tax purposes generally will depend upon the status of the partner and the activities of the partnership. A partner in a partnership or an investor in any other pass-through entity that will
hold our common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury regulations
promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such
change or differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue Service, or the IRS, will not challenge
one or more of the tax consequences described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital asset, which is generally property held for investment.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances, including the alternative minimum tax, the Medicare tax on net investment income or the
rules relating to &#147;qualified small business stock.&#148; Any U.S. federal tax other than the income tax (including, for example, the estate tax), and it does not nor does it address any aspects of U.S. state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> taxes. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules
applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;qualified foreign pension funds,&#148; or entities wholly owned by one or more &#147;qualified foreign
pension funds&#148;; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes
(and partners and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or
other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons that hold or receive our common stock pursuant to the exercise of any employee stock option or
otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">investors in pass-through entities (or entities that are treated as disregarded entities for U.S. federal
income tax purposes); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of
our common stock should consult their tax advisors with respect to the U.S. federal, state, local, estate and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on our common stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the
&#147;Dividend Policy&#148; section above, we do not intend to pay any cash dividends on our common stock to our stockholders stock in the foreseeable future. Distributions, if any, on shares of our common stock generally will constitute dividends
for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the
excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the shares of common stock. Any remaining
excess will be treated as capital gain, subject to the tax treatment described below in &#147;Gain on sale or other taxable disposition of our shares of common stock.&#148; Any such distributions will also be subject to the discussion below under
the section titled &#147;Withholding and information reporting requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion in the following two paragraphs
in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate specified by an applicable income tax treaty between
the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends that are treated as effectively connected with a trade or business conducted by
a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification and disclosure
requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively
connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of shares of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to
provide a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or a successor form) to the applicable withholding agent and satisfy
applicable certification and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on sale, exchange or other taxable disposition of shares of our common stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;Withholding and information reporting requirements&#151;FATCA,&#148; a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder&#146;s sale, exchange or other taxable disposition of shares of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
conduct of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in
which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on our common stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30%
tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital
losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed
U.S. federal income tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition
(or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market, within the
meaning of the relevant provisions of the Code, and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the
five-year period ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a &#147;U.S. real property holding corporation&#148; only if the
fair market value of its &#147;U.S. real property interests&#148; (as defined in the Code and applicable U.S. Treasury regulations) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other
assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax purposes, or that we are likely to
become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup withholding and information reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We must
report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on shares of our common stock paid to such holder and the tax withheld, if any, with respect to such distributions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is not a
United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on shares of our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will comply with
such procedures if it provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable IRS Form <FONT
STYLE="white-space:nowrap">W-8),</FONT> or otherwise meets documentary evidence requirements for establishing that it is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, or otherwise establishes an exemption. Dividends paid to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal income tax, as described above in &#147;Distributions on our common stock,&#148; generally will be exempt from U.S. backup withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding will generally apply to the proceeds of a disposition of shares of our common stock by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> unless the holder certifies its status as a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or
operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the
information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated
under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded
or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding and information reporting requirements&#151;FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax at a rate of 30% on payments of dividends on our common
stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the
foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Such withholding may also apply to payments of
gross proceeds of sales or other dispositions of shares of our common stock, although under proposed U.S. Treasury regulations (the preamble to which specifies that taxpayers, including withholding agents, are generally permitted to rely on them
pending finalization), no withholding will apply to payments of gross proceeds. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An
intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the
possible implications of this legislation on their investment in our common stock and the entities through which they hold our shares of common stock, including, without limitation, the process and deadlines for meeting the applicable requirements
to prevent the imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any of their pledgees, donees, assignees and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are
traded or in private transactions or by gift. These sales may be made at fixed or negotiated prices. The selling stockholders may use any one or more of the following methods when selling or otherwise transferring shares: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which a broker-dealer will attempt to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales to a broker-dealer as principal and the resale by the broker-dealer of the shares for its account;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions, including gifts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">covering short sales made after the date of this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> distribution
in accordance with the rules of the Nasdaq Global Market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in options transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method of sale permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell shares under Rule 144 of the Securities Act, if available, rather than pursuant to this prospectus. The selling
stockholders shall have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if it deems the purchase price to be unsatisfactory at any particular time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and their pledgees, donees, transferees or other successors in interest, may also sell the shares directly to market makers acting as
principals and/or broker-dealers acting as agents for themselves or their customers. Such broker-dealers may receive compensation in the form of discounts, concessions or commissions from the selling stockholder and/or the purchasers of shares for
whom such broker-dealers may act as agents or to whom they sell as principal or both, which compensation as to a particular broker-dealer might be in excess of customary commissions. Market makers and block purchasers purchasing the shares will do
so for their own account and at their own risk. It is possible that the selling stockholder will attempt to sell shares of common stock in block transactions to market makers or other purchasers at a price per share which may be below the then
existing market price. We cannot assure that all or any of the shares offered in this prospectus will be issued to, or sold by, the selling stockholders. The selling stockholders and any brokers, dealers or agents, upon effecting the sale of any of
the shares offered in this prospectus, may be deemed to be an &#147;underwriters&#148; as that term is defined under the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required
to pay all fees and expenses incident to the registration of the shares, but excluding brokerage commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders, alternatively,
may sell all or any part of the shares offered in this prospectus through an underwriter. The selling stockholders have not entered into any agreement with a prospective underwriter and there is no assurance that any such agreement will be entered
into. If the selling stockholders propose to sell shares to an underwriter, we will be required to amend this prospectus to reflect the terms of the underwritten offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may pledge shares to brokers under the margin provisions of customer agreements. If the selling stockholders defaults on a margin
loan, the broker may, from time to time, offer and sell the pledged </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares. The selling stockholders and any other persons participating in the sale or distribution of the shares will be subject to applicable provisions of the Securities Exchange Act of 1934, as
amended, and the rules and regulations under such Act, including, without limitation, Regulation M. These provisions may restrict certain activities of, and limit the timing of purchases and sales of any of the shares by, the selling stockholder or
any other such person. In the event a selling stockholder is deemed an affiliated purchaser or distribution participant within the meaning of Regulation M, then the selling stockholder will not be permitted to engage in short sales of common stock.
Furthermore, under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously engaging in market making and certain other activities with respect to such securities for a specified period of time prior to the
commencement of such distributions, subject to specified exceptions or exemptions. In addition, if a short sale is deemed to be a stabilizing activity, then the selling stockholder will not be permitted to engage in a short sale of our common stock.
All of these limitations may affect the marketability of the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling stockholders against certain liabilities,
including certain liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed with the selling stockholders to keep the Registration Statement of which this
prospectus constitutes a part effective until such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the Registration Statement or may be sold under Rule 144 without manner of sale
restrictions or volume limitations, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a selling stockholder notifies us that it has a material arrangement with a
broker-dealer for the resale of the common stock, then we would be required to amend the registration statement of which this prospectus is a part, and file a prospectus supplement to describe the agreement between the selling stockholder and the
broker-dealer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December 31, 2020, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are
incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we have filed with the SEC. Certain information in the registration statement has been omitted from
this prospectus in accordance with the rules of the SEC. For further information, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Statements contained in this prospectus or
incorporated by reference concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed or incorporated by reference as an exhibit to the registration statement, we refer you to
the copy of the contract or document that has been filed. Each statement in this prospectus or incorporated by reference relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains a
web site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers like us that file electronically with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting and information requirements of the Exchange Act and, as a result, we file periodic reports, proxy statements and other
information with the SEC. These periodic reports, proxy statements and other information will be available for inspection on the web site of the SEC referred to above. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom132252_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by
referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede the information already incorporated by
reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including all filings made
after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except as to any portion of any future report or document that is not deemed filed under such provisions, after the date of
this prospectus and prior to the termination of this offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1812364/000156459021015518/rlay-10k_20201231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2020, as filed with the SEC on March&nbsp;25, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information specifically incorporated by reference in our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1812364/000156459021015518/rlay-10k_20201231.htm">Form
 10-K</A> for the year ended December 31, 2020, from our <A HREF="http://www.sec.gov/Archives/edgar/data/1812364/000156459021018016/rlay-def14a_20210519.htm">Definitive Proxy Statement on Schedule 14(a)</A>, as filed with the SEC on April 7, 2021;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1812364/000119312521118438/d110953d8k.htm">Form 8-K
</A> (other than information furnished rather than filed) filed with the SEC on April 16, 2021; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1812364/000119312520191867/d948089d8a12b.htm">Form
 8-A</A> (File No. 001-39385) as filed with the SEC on July 13, 2020, including any amendments or reports filed for the purpose of updating this description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1812364/000156459021015518/rlay-ex43_903.htm">Exhibit
 4.3</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, as filed with the SEC on March&nbsp;25, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless specifically stated to the contrary, information that we furnish (and that is not deemed &#147;filed&#148; with the SEC)
under Items 2.02 and 7.01 of any Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including the related exhibits under Item 9.01, is not incorporated by reference into this prospectus or the registration statement of which this
prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference
in this prospectus, including exhibits to these documents. You should direct any requests for documents to Relay Therapeutics, Inc., 399 Binney Street, 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Floor, Cambridge, Massachusetts 02139,
telephone: (617) <FONT STYLE="white-space:nowrap">370-8837.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You also may access these filings on our website at <I>www.relaytx.com.</I> We do not
incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this
prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or
replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g132252g96c16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>1,883,487 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by
the Selling Stockholders </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May 6</B><B>,
2021</B> </P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g132252g10p63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g132252g10p63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )I2^F'8X0DE-! 0      %H< 5H  QLE1QP"   "^5(< E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@16QI>&ER("T@4F5L
M87D@+2!297-A;&4@4RTQ+F1O8W@X0DE-!"4      !#UUI<$??496CWV-SNB
M[PEC.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           #8   !V0          0                         !
M          =D   #8                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   #8     !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   V
M    4F=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    &.$))300,     !P;     0   *    !)   !X
MB.   !O_ !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT
M<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M          $  /;6  $     TRU(4" @
M                                   18W!R=    5     S9&5S8P
M 80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA9
M6@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(
M=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M   D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P
M!#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M           2<U)'0B!)14,V,3DV-BTR+C$
M                                         %A96B        #S40 !
M     1;,6%E:(                     !865H@        ;Z(  #CU   #
MD%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@
M                        9&5S8P         N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                         &1E<V,         +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                          !V:65W       3I/X %%\N !#/%  #[<P
M!!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                      */     G-I9R      0U)4(&-U<G8        $
M      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H
M &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4
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M@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@!%0)= P$1  (1 0,1 ?_$ !\  0  !@,! 0
M           %!@<("0H! @,$"__$ &<0   & @ " P4/#0X#!0<"!P$" P0%
M!@ '"!$2$Q8)%!4ADQ@9,5%355976'.1E9;4U1<:(C0U-T%2E+&RUM<*(R14
M87%T=G>7L[6VTCB!TR4R.9+1)C-"=;?!\$/Q)S9$<H.AM/_$ !T! 0 !!0$!
M 0             ! @0%!@<#" G_Q !D$0 ! @,#! H)$ 8'!@4$ @,! @,
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MRSUJ8#ZW'DMNF4SJ4..NJ;OW"XN[>-RF6$=&AB$,0AB$,0AB$4KWK]Y'<?\
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M>>>#+="IA1JMYI"0N5<I-,$ +".T9,Y0V/EM9",@,NE7E*HC)VW5%)F9:92
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M/8XFB&I&;<42>Q^"42[ZO<1NMNJVI=5*[7B:A%2%.0Q3%,4#%$H@8!*;QE,
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MXORLN\767RZPRX7Y8*$N]G&D+SK 6MQ09<K?:!<60@IJM1JHXA0*5*!!%%*
M"J%0 4115 !>%*&@ )%1@8@.7,1&\3W!3_P^J]_:KL__ #5GGQ;LX?[^S/\
MTVS?X*HW*Q?<"/E'/I1KO]V__P#$>W-_5[5'_P!,ZQG?MA?_ (>V1^\6K_[G
M-1@+8_I%[O&?X8C$RD4#JI$-SZ)E4RFY#RYE,<I1#GZ(>(1\8<ASJ:C1).^
M2.4 F,6:[PKQ:(S/\3'#]P*L[1OZ'HHRE9DN&ZJVV<L41JF7M@PDJ,CM_4&L
M=:0DW+[I4LSF0M<6E>+5-[ DZ( U)>-8PA:Z5=VG)FSC.3>4&7"Y6PGIXMS+
M>44W*,2[EJ-2H?;#=D6M:-HO2[5CB7#<LXJ2EFI!N>_VH.+?+Y",W3+3+$B%
M/I:JV9="U*2TI12:NM-MA2G@LE2;ZE.*;%TI "22*"9:WW+C3T]?PK1;]M$8
MV$:7YR[;)KTI:9VC5:?9M*5F+W5K%6!B;0K&ZRM@[5F9* 8/:_;).44I:L,Q
MFU7$D^?5ZWF-D^V&9#;)D;,#CZY%*%%,X&;-FIN5MF9<L>TP^[+!=I2O8IEM
M]:)F4;:$Z'G&4I:0V_ZILMI3H0'':)#A();O.I0I@!UJZA5&E!U13N5%100D
MFM1!=2]SHX>=I72LTL+KMVLN)VCR%ZF%[%*5R/E*DRD=^733-9BWE4;ZVD;
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M,X<]YK.FX)+J-.^7 MSJ&1ZY7H=8;Z^8+JVFE.M!MY3:%.LH7G4MN%(+C:7
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M25*W0I#<K43NY7_#7JW^W&*_T%?LY!DE_2+W[HK^/+QS[]-7_AODQ_XYE?\
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M$H0VE( 0E"0$I"0 D  4 CR(J2I6Z4352E;HJ)Q)43I)))).DDUCY0  #D
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MI4 T-14:#0BHU&A(KJ)C2PI0K0D5%#Q@FIKKQUQW!=8  H*J 4"@0"@<P !
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MG1'ZO?"L',>7U(KKXOP?_P Y-?P?@$>0<Q]$>0<_0SOFPZ/_ ..MG]]EC_\
MZZA^1HTG28YUEQ[HD?D7/IB-5W.QQHL,0AB$,0B==:_?%H/]=:K_ )ZPRWF_
M<LS^[O?PU1Z,_K6OE$?2$?KAK?:JW\B*O_\ HIL^*$Z1RCSQWR+:!\0C_..;
M,G0.0>:+>.,F$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0B>]?_==?^B&_P 5
M/,=:/ZMOOS]$Q6C2>3ZQ%0+4'..)Z/B<$'T1#Q\C!X^7H^(1\0^++60]T?X%
M_5%K:7N8\2T?6(IYF;C7H8A#$(8A#$(8A#$(8A#$(8A#$(8A#$(8A#$(8A#$
M(8A#$(8A#$(8A#$(8A#$(8A#$(8A#$(8A#$(8A#$(8A#$(8A#$(FRICR<._>
MTOTS?^HYC;2[5KOE>8=49:RNV>[U'G,12UB/>*0<_%WP0>7\O04]'T\L&.V5
MWG^I,7%J?J$_*#Z*HI_ES&!BB6R^)'0^G99K [.VK3J9-O699%O#S$H1.3,P
M44422>'8HE6<HMEE45B(+K)IIK&25*D8XIG MVQ(S4PDK98=<2%%)4E%4WA2
MHJ2!45%1O1IV46R#D1DE--2.4N5%CV-.O-!]N4G)I*9A3)4I"72R@+<0VI2%
MA"UI2E92H(*BE5*;^;OX/_= Z^^,'/S//;L5:'O1_H#THU_U[-B;X_9/?.E_
M90\W?P?^Z!U]\8.?F>.Q5H>]'^@/2AZ]FQ-\?LGOG2_LH^EGQR<(K]VV9-N(
M#7(N'2R;=$%I@S1(553 0@'<ND$6R)1,( *BZR:9>?,QP#!LJT "=J/T ).X
MWAIT$X\7EBMK9HV*7G6V6\O<G"XZM+;85.YM)6LA*07'$(;0"2 5+4E(TJ4!
MC%U1#D4(51,Q3D.4IR'(8#$.0P 8IBF*(@8I@$!*8!$! 0$!Y#F.T:8Z:"%
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M=DNYBVRAY:2;2:IXQ%==D*"N^34PIA;(#:"RM10ZZJ^<V2XRVV AM)4;ZG2
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MX2:QC]\9NS9(MT4SK.Q0[X6=D(T*L"#DR6"RAGY6:;ET2[H=*5+4HI2H)2*
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M",W;K]/)P[NQ/V4;"Q@-*I7DFL4DX*^7<5-2^;.)! 2$BF%!A7G(\&\=%"E
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M.51\QM\S/.GD]2)UL\CI9^V>,B"1ZQ:.8..=-%'$A4*D&H ((H1B#45UG13
M@XCGCPF&4M$75).*TFZXAS%"KI-4$T2=*3B%:4E0H8O#Q%M%E/'/<>(F UA
MUCA8KUSEMPWJTK,XR:J$+1Y4*A$56L6"\.Y.=6V;)PM":0MAF*]7]?22<K+-
M9MQ&7*16IB3JT,HXA9W=!<TE0%<,  34UWJT!TX5IC0&[E&VUJ*GEMH;!2DE
MPJH"JHO7&PIU24)O*);0NZ0 1520;9HSC$XS;',QMEB-!,HK6<O-UY=K6[/J
M#;[#9+*J.[CPG5^70EY52SM(EA81B.(78<Z1=6H@Q@T]"VP';"8:J3;NHT7E
M$]H*5&\=&&&! TG43KQQ$EEJ[VV[ .^ DD!>@5K2J4XUQJ3JK+FFN+[?W%%
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M\="E.*HF;CS$0(S5=N^1#<VH<R=(%$TW"A4T-2C :S11PY*GBA<3C[:C 5!
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M92$(:*U. J2DV2^?;MO<W+_WLI_LYS*^I=?OE'B?_P!L<9]F:Q_9X[_YH1^
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MNM61LNUAVMB2K]B2E'T ]CTVCKRVVD5JE6E2=&E22,!0XD@U&BE16*@V:T.
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MW-6C[&AB$,0BJ<)]RV?O0?G'+)SMU<L;1*>YVN]^LQI:_NIW[_?"M_9%=?\
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M;S[KLBS6MUYA=2HU3&0]3067"S-I4VETMA=RM0W-.LS"A0T)9;0E]0H-RL5
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M\00=,:;F7<06W 1@06U@CE%W#D.,?'V&NWL/M/R?EOFF3MECNS7C6O3AF7>
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M5WG^M$7%J?J$_*#Z*HD#+F,##$(^1^@=RQ>MDA*"KAHX03$XB4H'51.F03&
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M(!G\>*H..FH<L4X*F=KR#F@1(9@YDU^?2$'1EE4P 0 6@\N9EUR@JL5KB;I
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M9%94"%$G?XB8#EQUHWKK52"*JT C&@J=)PU#>UG>RMEE)4]0$&B34G"E304
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MH5S;45K8]3V%LU0ZUQKA^GKBK?\ 9K1PRG&Y$)!HWL*;"7DVCHJ4;.@J&)-
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M@@BJS=JE13C0J2% *(J0>V52M2FII@3$*GE%EUA)<2V\M+BT7C<6IL+2RM:
M;JG&D..H0L@E(== (#BP87L[N6]DVSMC8VQKQMRG6^,M^RJI<6-9MFN)B;(]
MJU?XE=*;T&BW5PZO:C"8BHFHZ7BM/TPL-#P+> K<M97RS5^XMUA;N%%7B0LA
M-\.  J!O!0(-0K C&A&(H*&*V+2=ET-)9<F&BRXE]I33BF\U,H0I*)EH)4"E
M])ND.@A8 H",(S%$(1,I4TRE(F0I2$(4 *4A"@!2E*4   *4
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M)-?N[W\-48)G]:U\HCZ0C]<-;[56]Y5_0-GQ0G2.4>>.^1A<[H-+;G:L^&N
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MZ0_ .*'4>8PH=1YC#D/I#\ XH=1YC"AU'F,.0^D/P#BAU'F,*'4>8PY#Z0_
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ME67KI:OE?9OI3&UD]T=\8YZ<+XX".8^E$[46H,EI5<HR]N('>AO&G<K.0?\
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MJA&E=64Y"UA@_F6R\BE;P/%H._3 BN\0=S@:5@95T JH* @&JDXDA1%T7JJ
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MI6J\Y>N[EM:PDW$K4%.% 0@J 0%J2%J0DE0O4*8#E*8 , &*!@ Y#IF !#F
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M0"(]6,B4-O-..SY<;0M*U-H8S:EA)K="\\J[6E";IH":4-"-N]<.398.?/\
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M>J&T9KN1YQ#S>/"%[>M1\A/_ $-C;<OW5/EZH;1FNY'G$/-X\(7MZU'R$_\
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M(W;NF&OUIB(NQ[BUE%U5BDR@]I6^(7AXZG2L[-TP;5KVJ7.-@90U<D;K8W$
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MD<.E2H-4#O9!=NV*LY7.1%ND94#K+'(DD4QS%*.QE:4)3>-,!J^NF)W@,8\
M"=$?*K:JN@111>RU]%-)Z^C53JS,:F5*1BX]:6DX]0QW( 1]&Q39Q*2#,W)R
MRCFZ[YRDDU145*SJ*5KHY.8XT&&.) XXD(4J]1)-T7E$# )O!-XG0 5*2D'0
M20-)$0]ML&A/&D*_9WBG.V-ED#1-<>MK/!KM+!*D.8AHR#<I/SHR\B4Y3E,Q
MCSN'13$.4R0&*(!&>;(!"AC@,1B=6G2-\<<+IQPT"OY\W+$W9Z U%1OQ3#)A
M#$(8A#$(@$W;*K6EXMM8[-7J^YG'0L81O.34;$+S+X#)%%E$I2#INI).P,X0
M*+9F598#+HEZ'-5,#4+<0@@*-"=&C'>UQ(!()U<\=3VZII'?)J6BN)J1C>7=
MR9#SD60\<TKZB*,^Z?E,Z S)M!K.&Z4RNY!)*+5<()OCH'5(4T9U&-32E:U(
MPI6N_7>/_:%U1%0DD5 K0TJ:D"NBI"20-^AU&(DXEHIH6/.[DX]J26=-V,4=
MP];(%DWKM)1=JSCC*JE!\[=((JK-FS455ETDE%$B'(0PA)<2*8Z=&C'DQQU>
M: 25&B02<3@*X $D\@ ))W@"3@(EZ1V'K^'1EW$O>Z9%-Z_(-HB>7D[3!,$8
M25>)]<SBYA5T_23C)%TB JMF+XR#I=(!422.0.EE)>; )*A04J:C FF!QTXC
MEK08P"5*K0$T%308 5 J3O"I J<*D#28BD=9ZU,#'!$6*!E1F(Q::B C9B.?
MC*PS9=NV<2\8#5RKW_%MW+MHW7D&G7-$5W39%18JBZ13REU"J4-;PJ-&(T:]
M?YP,001IB.9Z0AB$3WK_ .ZZ_P#1#?XJ>8ZT?U;??GZ)BM&D\GUB*@6G[G%]
M_)^8<M9#W1_@5]46MI>Y3WZ/.8H]89]K7F/?2Y1554-U39L00*993ES'F80$
M")D+]DH<0'H@)2@ G,4HY5]]+"+RL2<$I&DGZAK.--485AA3Z[B2$@"JE$$@
M"M-[237 ;^.J*6'V;-B81391A"^/D4R;I0P!^#F<'28"(!XA$"%Y^CR#T,QI
MM%ZN"&P.,+)Y[R?-&3%FR],7':Z]P!S73Y]XQU^J;._Q2*\@[^>Y'9%_@M=%
M?IQ/8V7[J[_E]"'U39W^*17D'?SW'9%_@M=%?IP[&R_=7?\ +Z$/JFSO\4BO
M(._GN.R+_!:Z*_3AV-E^ZN_Y?0A]4V=_BD5Y!W\]QV1?X+717Z<.QLOW5W_+
MZ$/JFSO\4BO(._GN.R+_  6NBOTX=C9?NKO^7T(?5-G?XI%>0=_/<=D7^"UT
M5^G#L;+]U=_R^A#ZIL[_ !2*\@[^>X[(O\%KHK].'8V7[J[_ )?0A]4V=_BD
M5Y!W\]QV1?X+717Z<.QLOW5W_+Z$/JFSO\4BO(._GN.R+_!:Z*_3AV-E^ZN_
MY?0A]4V=_BD5Y!W\]QV1?X+717Z<.QLOW5W_ "^A#ZIL[_%(KR#OY[CLB_P6
MNBOTX=C9?NKO^7T(?5-G?XI%>0=_/<=D7^"UT5^G#L;+]U=_R^A#ZIL[_%(K
MR#OY[CLB_P %KHK].'8V7[J[_E]"'U39W^*17D'?SW'9%_@M=%?IP[&R_=7?
M\OH0^J;._P 4BO(._GN.R+_!:Z*_3AV-E^ZN_P"7T([I[.F@. JLHPY '[(I
M".4S"'X0 XN5 */I")#<O2')%HNU%Y#9&^ % TXB5D#F,0;-EZ&CCM=X[FGA
M%P'RC3%5("=:V!@#QN4R1BG%)PW.("=%8H%,)>8<@.0Q3%,F<  #%'D(%.!B
M%R;+R7T!::C>4DTJDZC3BQ!W_!&+?85+KN*(-15)&%1KH<1$<SUCQAB$,0AB
M$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$,0AB$394_MAU[VE^F;,;:7:-=\KS"
M,M97;O=ZCSJB)VO[22]_)^BIEA+]LKO/]:(N+4_4)^4'T51(&7,8&&(0Q"-;
M7NSXCYH#6(<Q$ TXS$ $1$ $UVN'2$ ] !,!2@(AZ(%* ^@'+>,F/<CW',*\
MC:#3R>4Q^>/Z85?5UDW4D@9(,$ Z 56S:X-!O8 <I U 1CFU?K&$V'5MA.$Y
MAV:]UF)=3U;IS51@T/.5^!K-IM%TG1=R0%073JD= -G3F(;+I2D@T>+GC2N7
M#4&RN;FIEQAV72$#,.+"'7E!2@VI;C;;22$FHSA6H!1!2%  TK'SUDQDS(Y0
M67E$X)QWL[9DF[/V98[2I=DS\C(V;:MIVQ.YZ9HVM-E2]GM//2K:T3+[+RS+
M!UU :54BR\/%38;%J3&)O[5/2UHZMVTVY,R5;;H/H'M;8ZF:;:PKB1BGC JL
ME7EV"C*8(V\"/#&=3;UK# 62&U;M%PL.%;59Q!4!*H0Z2%);;=*2L!84;CE\
M%-+Z1N05&Z-FM+8[LF7RALEJ4MYL9%6F$/-96S<S9C:'I,VK:-E;;;DW9B4=
M8#DS9ZY=34T$"1>479YYN3 F%5D9\#E==2T!$&V-)%7N!JW+02S2,K\M'1E>
MDS\/9I5C/3$58G<:XLC=/?2*46>#7?0T@M76JI7(-[,V&,M3;3@2M8811K.(
M74K2I3B1.W%-H4E*@T=IJ*LX$K2%D4JW5>WL["%GN3DC)JRAF@NU^QTW(+9E
MI";EY:SYA6Q_MMBT)R5GW95=HM)RZ"994BX_)/KLYI8=*+21M:T;>&KV^G[N
M2CIRCF<<M:Y7):0F>]44(62<V*,2G45ZH[0<.2S5;)&OV#=I.])(LF\1?K-V
MZ;0&XFRTE,JFF2\0E(+BTI0*WTA"KA#H.*'+R5$HTI24DZ8Y'EMDRWDC;2;$
M3,NSKC5G6=-S$YFT(DIIRT99$\AVRG4+<$Y9HEGV&V9VJ1,NH><;0EHMUSB=
MQ4$?J7[N+S'HAL"OB <QY (UOD(@'H (@  (AXQ I>?/D'+4\J?=,K\@K^(8
M^U/T."?4MEF-[U0R)\/8T=0C-9FK1]C0Q"&(15.$^Y;/WH/SCEDYVZN6-HE/
M<[7>_68MVW]]TJ]_07G_ /T)Y1'JO0*::BGEC6YV)W,W;]CO7%YO6K;(6J&W
M+_LRXRG#VC2Y=A1EXJL;$@.':OV^P7'9\!7TME>%C16J[!'UVI(SRE6KZZP3
M[=HO-RQ748!Y-\;QTCCWZ&NL'$8T,5)5=IHJ4W=TD$4*2#@JH! ."@+R575
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MM%393-EJ5VU?MJF;)J#ME9I&'M53F:N#\\0_7>5M^RG$&KMOFYEM3B474A1
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M)4[>[5)?8TM*M]SC6O# ^?H0;%DQN);<1HNM#1D;TJJO. TH"!7>&- H5K4
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?0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g132252g96c16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g132252g96c16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[23\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )."^E$ X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !D0
M! ,          0                         !              0#   !
MD0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MD0    !29VAT;&]N9P  ! ,    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   9$     4F=H=&QO;F<
M  0#     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   ".$))300,     !J*     0   *     ^   !X   =$   !IN !@  ?_8
M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
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MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME4^7C;*P:\8?W[XX=?W*&\U2?D>3\YE'Y-^G$&CWV\= 'V&QAU\+%>#]7UT
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MFV;ND6:8(F5*W!9==12NJ0QRHY=>XA^!YL.!VJ>/(CW)R!R1QP?7]OZ\G3Z
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MQ'WYD'ZDSR/W_1_7E^'+=DS-+U;@ W4^M!3  E'GK. (" " @/(9T @(#\!
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M^&_43Z>VFMT3$HV?;:JC(^H]\-4E"BY0VI0FK)G(3+M$#&\@;W .*_L%%,@
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M*Z;8GGUXJ2_R_9]CS^CV&>V3@US8^'^P_P"4(?C[Z!VL ?1\?\$^_P!/T?\
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M&V"/3=D2.)169N2F,@_CG/A^:#J.?).&3D"B)!60.9,3)B4PZ9MUI*=F:K,
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M_P#1^_=\\+]K3$Q27<Q2K2R,^I>R=?V=@_:QMBC6C\H3-&V%578L71B-Y!F
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@8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
